Congressional Investigation into Alzheimer’s Drug Aduhelm Faults the F.D.A. and Biogen

0
19

The report said the F.D.A.’s approval process for Aduhelm was “rife with irregularities” and criticized Biogen for setting an “unjustifiably high price.”

LEAVE A REPLY

Please enter your comment!
Please enter your name here